ORGN 141 |
| Brian H. Keogh Jr., Ryan J. Rafferty, and Richard M. Hyslop. Department of Chemistry and Biochemistry, University of Northern Colorado, Greeley, CO 80639 |
| 6-Thiopurine (6-TP) is a chemotherapy agent used in the treatment of acute lymphocytic leukemia, Crohn’s disease, inflammatory bowel disease and non-Hodgkin’s lymphoblastic leukemia, but a variety of side effects, including jaundice, have been reported. The onset of jaundice has been attributed to the noncompetitive inhibition of UDP-glucose dehydrogenase (UDPGH) by 6-TP and its metabolites, resulting in the inability of the body to conjugate UDP-glucuronic acid to bilirubin for excretion purposes. The goal of this project has been to synthesize pharmacologically active 6-TP analogs with reduced UDPGH inhibitory properties. Several compounds have been synthesized via a modified Traube synthesis and a modified Acker and Castle method. All analogs were characterized by NMR, IR, UV, and LC-MS. |
|
New Reactions and Methodology, Metal-Mediated Reactions, Heterocycles and Aromatics
8:00 PM-10:00 PM, Sunday, March 28, 2004 Anaheim Convention Center -- Hall A, Poster
Sci-Mix
Division of Organic Chemistry |